Drug Revenues Higher Than Expected! AbbVie Soars and Raises Earnings Forecast for 2025!
Reading Time: 4 minutes
The pharmaceutical company AbbVie (ABBV) announced its business figures for the 1st quarter of 2025 on Friday, April 25, 2025, before the market opened. Thanks to its strong drug portfolio in the areas of immunology, neuroscience, and oncology, the company exceeded Wall Street estimates and raised its earnings outlook for the entire fiscal year 2025. The stock rose by over 3% to $186.06 by the close of trading. Total revenues rise by 8.4% in Q1 2025 The pharmaceutical giant reported a net revenue of $13.34 billion for the 1st quarter, surpassing...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
